

PROUS SCIENCE INTEGRITY®

PROUS SCIENCE INTEGRITY® + BIOMARKERcenter™

DECEMBER 2009 ENHANCEMENTS



THOMSON REUTERS

ENHANCEMENTS – DECEMBER 2009

The December 2009 release of Prous Science Integrity[®] and BIOMARKERcenter[™] is designed to further integrate the portal into the scientist's workflow by:

- Enabling users to quickly and easily consolidate bibliographic findings and integrate them into their citation management databases.
- Advancing the way users search, retrieve, display and export information within Integrity.
- Providing instant insight to key relationships among compounds, mechanisms, patents and pharmacology results.

ENHANCEMENTS – DECEMBER 2009

- Literature
 - Export citations to bibliographic management software.
 - Links to Web of Knowledge.
- Patents
 - Condition and Subject Matter added as search fields, displays, export and charting options.
 - Compound Mechanism of Action added as a charting option.
- Experimental Pharmacology
 - Mechanism of Action field added to displays and export.
 - Charts for Drug Mechanism of Action and Reference Type.
- Clinical Studies
 - Charts for Intervention Type and Reference Publication Year.

ENHANCEMENTS – DECEMBER 2009

- BIOMARKERcenter
 - New search fields to enable intuitive searching using drug names, mechanisms of action or genetic variations to retrieve relevant biomarker uses.

In more detail:

- Search for “Product Links”
 - Retrieve biomarker uses that have been intellectually linked to a specific drug, a mechanism of action, product category or therapeutic group
- Search for “Genetic Variations”
 - Find biomarker uses that involve specific genetic variations such as polymorphisms or epigenetic changes.

Records Retrieved

0 DailyDrugNews Records, 0 Prous References Records, and other records

Biomedical Literature Search Results

Sartore-Bianchi, A.; Martini, M.; Molinari, F.; Veronese, S.; Nichelatti, M.; P.; De Dosso, S.; Mazzucchelli, L.; Frattini, M.; Siena, S.; Bardelli, A.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR tyrosine kinase inhibitors
Cancer Res 2009, 69(5): 1851

RELATED INFORMATION

[DRUGS & BIOLOGICS](#) [BIOMARKERS](#)

Pritchard, C.; Mecham, B.; Dumpit, R.; Coleman, I.; Bhattacharjee, M.; Cheung

Conserved gene expression programs integrate mammalian prostate development and cancer progression
Cancer Res 2009, 69(5): 1739

Hino, R.; Uozaki, H.; Murakami, N.; Ushiku, T.; Shinozaki, A.; Ishikawa, S.; Takada, K.; Fukayama, M.

Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to increased proliferation in gastric carcinoma
Cancer Res 2009, 69(7): 2766

RELATED INFORMATION

[GENOMICS](#) [TARGETS & PATHWAYS](#)

Attard, G.; Swennenhuis, J.F.; Olmos, D.; Reid, A.H.; Vickers, E.; A'Hern, R.; Riisnaes, T.; Commen, N.B.; Hawche, G.; Jamieson, C.; Thompson, E.; Sipke

Dearnaley, D.; Kaye, S.B.; Cooper, C.S.; Molina, A.; Cox, M.E.; Terstappen, L.J.W.M.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with prostate cancer
Cancer Res 2009, 69(7): 2912

RELATED INFORMATION

[GENOMICS](#) [TARGETS & PATHWAYS](#)

Sos, M.L.; Koker, M.; Weir, B.A.; Heynck, S.; Rabinovsky, R.; Zander, T.; Seeger, J.M.; Wrona, M.; Frommolt, P.; Michel, K.; Peifer, M.; Mermel, C.; Girard, L.; Peyton, M.; Gazdar, A.F.; Mitchell

Kashkar, H.; Pao, W.; Meyerson, M.; Thomas, R.K.

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and inhibition of p38
Cancer Res 2009, 69(8): 3256

RELATED INFORMATION

[DRUGS & BIOLOGICS](#) [BIOMARKERS](#)

http://integritytest.prous.com - Export Center - Microsoft Internet Explorer

Export Center - Literature

This feature allows users to export selected data from Integrity for use in other applications. Up to 100 records can be exported at a time from this Knowledge Area, either as full pages of records or as selected records (by utilizing the record checkbox feature).

Follow these steps to export data:

1) Use the pulldown menu to choose an export format.

Export type:

- Excel
- Excel
- Word
- Endnote
- Reference Manager
- Refworks

2) Check the fields you wish to export:

- Author
- Primary Author
- Title
- Citation

Journal (abbreviated)

Volume

Issue

Page Numbers

Literature:

- New export formats -- EndNote, Reference Manager and RefWorks – to facilitate integration of Integrity citations into user citation management databases.
- Links to Web of Knowledge.

Patent

Subject Matter

Select Value

- Title
- Prous Science Abstract
- Original Abstract
- Title/Abstracts
- Condition
- Subject Matter

Applicant Data

- Inventor

Patent

Priority

- Last Updated
- Available Since

PROUS SCIENCE Integrity®

Knowledge Areas Quick Search [go]

Records Retrieved 5 in Patents

Patent Search Results


Query > Subject Matters = "Methods of Use" AND Drug Name = "Thalidomide"

Patents (Applicants)	Title	Subject Matter	Condition	
<input type="checkbox"/> JP 2006169183 * (Toyohashi University of Technology)	Medicinal preparations for the prevention of diabetic cataract	Methods of Use	Retinopathy, diabetic	Thalidomide
<input type="checkbox"/> EP 1755599 JP 2007533759 WO 2005102333 * US 2005239719 (Celgene Corp.)	Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension	Methods of Use	Hypertension, pulmonary	Thalidomide
<input type="checkbox"/> JP 2007510670 EP 1684758 EP 2077112 WO 2005046593 * CA 2545128 US 2007208057 (Celgene Corp.)	Methods and compositions using thalidomide for the treatment and management of cancers and other diseases	Methods of Use	Cancer	Thalidomide
<input type="checkbox"/> WO 2005046686 * (Celgene Corp.)	Methods and compositions using	Methods of Use	Cancer	Thalidomide
<input type="checkbox"/> JP 2007509170 EP 1680132 US 2005119194 WO 2005039497 * (Celgene Corp.)				

Patents:

- Condition and Subject Matter added as search fields and to displays.
- Subject Matter, Condition and Compound Mechanism of Action as new chart options.

- Applicant/Assignee
- Inventor
- Priority Date
- Applicant Country
- Applicant State or Province (U.S. + Canada)
- Basic Patent Publication Year
- Expiration Date
- Subject Matter
- Condition
- Compound Mechanism of Action





Experimental Pharmacology:

- Drug Mechanism of Action field added to results display, export and filter options.
- Option to filter by Reference Type to focus on data from literature or patent sources.


Records Retrieved 1281 in E

Experimental Pharmacology Search Resu

Drug Name	Mechanism of Action	Pharm Activit	Value	Details
<input type="checkbox"/> 103464	HMG-CoA Reductase Inhibitors	Nuclear activati		
<input type="checkbox"/> 248717	HMG-CoA Reductase Inhibitors	Cholest inhibiti		
<input type="checkbox"/> 248717	HMG-CoA Reductase Inhibitors	Hydroxymethylglutaryl-CoA [HMG-CoA] reductase, inhibition	IC-50 26 ± 4.00 nM	Ref. 246
<input type="checkbox"/> 407169	HMG-CoA Reductase Inhibitors	Cholesterol production, inhibition	Hepatocytes, rat	Mevalonate incorporation assay IC-50 0.190 nM Pat. 6
<input type="checkbox"/> 407169	HMG-CoA Reductase Inhibitors	Hydroxymethylglutaryl-CoA [HMG-CoA] reductase, inhibition	Liver, rat	IC-50 0.610 nM Pat. 6
<input type="checkbox"/> 407169	HMG-CoA Reductase Inhibitors	Cholesterol production, inhibition	L6 rat myoblasts	Acetate incorporation assay IC-50 0.940 µM Pat. 6
<input type="checkbox"/> 407170	HMG-CoA Reductase Inhibitors	Cholesterol production, inhibition	Hepatocytes, rat	Mevalonate incorporation IC-50 0.740 nM Pat. 6
<input type="checkbox"/> 407170	HMG-CoA Reductase Inhibitors	Hydro [HMG-inhibit		
<input type="checkbox"/> 407170	HMG-CoA Reductase Inhibitors	Chole. inhibiti		
<input type="checkbox"/> 407171	HMG-CoA Reductase Inhibitors	Chole. inhibiti		
<input type="checkbox"/> 407171	HMG-CoA Reductase Inhibitors	Hydro [HMG-inhibit		
<input type="checkbox"/> 407171	HMG-CoA Reductase Inhibitors	Chole.		

Filter by Statistics

- ▶ Pharmacological Activity
- ▶ Parameter
- ▶ Material
- ▶ Method
- ▶ **Reference Type**
- ▶ Product in Studies
- ▶ Drug Mechanism of Action






Export to Excel



Snapshot Tool

Reference Publication Year

Condition = "Dementia, Alzheimer's type" AND Population No. = from 500



Clinical Studies:

- New Filter by Statistics options (Charts) to refine search results and elucidate data relationships.



Print Chart



Help

↑ Check All

0 8 16 24 32 40 48 56 64 72 80

3716 Records in Biomarkers

**BIOMARKERcenter
 User Resources**

The following resources are available to assist you with your discovery of BIOMARKERcenter:

- [Introduction to BIOMARKERcenter - Fact Sheet](#)
- [Find out more about BIOMARKERcenter](#)
- [How do I use BIOMARKERcenter](#)
- [BIOMARKERcenter Frequently Asked Questions](#)
- ["July 2009 BIOMARKERcenter Enhancement Summary"](#)

BIOMARKERcenter
 ENHANCEMENTS
DECEMBER 2009

CLICK HERE FOR DETAILS

New "Product Links" search fields

Advanced Search

Biomarker

Role ▶ "Predicting Treatment Efficacy"
 Mechanism of Action ▶ "Anti-EGFR"

- Select Value
- Biomarker
- Name
 - Type
 - Biological Process
 - Description
 - Mechanism Modifier
 - Last Update
 - Available Since
- Biomarker use
- Use ID
 - Indication
 - Population
 - Role
 - Validity
 - Technique
 - Substrate
 - Kit
 - Genetic Variation
 - Product Name
 - Mechanism of Action
 - Product Category
 - Therapeutic Group
 - Authority

Find biomarkers that can be used for predicting or monitoring efficacy or safety of various treatments.

Biomarker Use Record

Biomarker [GTPase KRas](#)
 Use ID 22284

Summary

Role	Predicting Treatment Efficacy
Indication Type	Diseases
Indication	Cancer, colorectal metastatic
Population	All
Technique	Genotyping
Substrate	DNA
Validity	Early Studies in Humans

Sources

- Displaying the most recent 5 of 10 references
- [Impact of Fc\(gamma\)RIIIa-Fc\(gamma\)RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan](#)
 - [PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer](#)
 - [FLOX + cetuximab \(Erbix\) for patients with metastatic colorectal cancer and wild type KRAS \(NCT00680582\)](#)
 - [EGFR, DCC, and K-RAS mutations as predictive factors for cetuximab sensitivity in metastatic colorectal cancer \(mCRC\)](#)
 - [Association between EGFR gene copy number and KRAS status and impact on outcome of metastatic colorectal cancer patients treated with cetuximab](#)
- [View all 10 supporting \(+\) references](#)
- Refs +
- Pats +
- [K-ras and B-raf mutations and anti-EGFR antibody therapy](#)

Product Links

Name	Type	Sources
Anti-Egfr	Mechanism of Action	Refs + <ul style="list-style-type: none"> • PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from irinotecan for patients with metastatic colorectal cancer Pats + <ul style="list-style-type: none"> • K-ras and B-raf mutations and anti-EGFR antibody therapy

Retrieve biomarkers using gene names or genetic variations such as polymorphisms.

3716 Records in Biomarkers

BIOMARKERcenter
User Resources

The following resources are available to assist you with your discovery of BIOMARKERcenter:

- [Introduction to BIOMARKERcenter - Fact Sheet](#)
- [Find out more about BIOMARKERcenter](#)
- [How do I use BIOMARKERcenter](#)
- [BIOMARKERcenter Frequently Asked Questions](#)
- ["July 2009 BIOMARKERcenter Enhancement Summary"](#)

BIOMARKERcenter
ENHANCEMENTS
DECEMBER 2009

CLICK

New "Genetic Variations" search fields

Advanced Search

Session

Biomarker

Product Name	"Fluorouracil"	<input type="button" value="Index"/>	<input type="button" value="AND"/>
Role	"Predicting Treatment Toxicity"	<input type="button" value="Index"/>	<input type="button" value="AND"/>
Variation Type	"Polymorphism/mutation"	<input type="button" value="Index"/>	<input type="button" value="AND"/>

Select Value

Biomarker

- Name
- Type
- Biological Process
- Description
- Mechanism Modifier
- Last Update
- Available Since

Biomarker use

- Use ID
- Indication
- Population
- Role
- Validity
- Technique
- Substrate
- Kit

- Genetic Variation
- Product Name
- Mechanism of Action
- Product Category
- Therapeutic Group
- Authority

Active Development

Biomarker Use Record

Biomarker	Vascular endothelial growth factor A
Use ID	48184

Summary

Role	Predicting Treatment Toxicity
Indication Type	Adverse Events
Indication	Cheilitis
Population	Cancer, Esophageal
Technique	Genotyping
Substrate	DNA
Validity	Early Studies in Humans
Sources	Refs + VEGF G-1154A is predictive of severe acute toxic carcinoma in Japanese patients

Genetic Variations

Gene Name	Vascular endothelial growth factor, transcript variant 4		
Synonyms	VEGF, VEGF-A, VEGF165		
Variant Name	Type	Sources	
-1154A>G	Polymorphism/mutation	Refs	+ VEGF G-1154A is predictive of severe acute toxic carcinoma in Japanese patients

Product Links

Name	Type	Sources	
Cisplatin	Product	Refs	+ chem Japan
Fluorouracil	Product	Refs	+ chem Japan